摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

11-deoxy-11-imino-4-deoxy-3,4-[2-spiro-cyclohexyl]-(1H)-imidazo-(2,5-dihydro)rifamycin S | 1574166-73-6

中文名称
——
中文别名
——
英文名称
11-deoxy-11-imino-4-deoxy-3,4-[2-spiro-cyclohexyl]-(1H)-imidazo-(2,5-dihydro)rifamycin S
英文别名
——
11-deoxy-11-imino-4-deoxy-3,4-[2-spiro-cyclohexyl]-(1H)-imidazo-(2,5-dihydro)rifamycin S化学式
CAS
1574166-73-6
化学式
C43H56N4O10
mdl
——
分子量
788.938
InChiKey
ULUHZYFIKWGIEW-QRVOVNQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.01
  • 重原子数:
    57.0
  • 可旋转键数:
    2.0
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    209.09
  • 氢给体数:
    6.0
  • 氢受体数:
    13.0

文献信息

  • [EN] COMPOSITIONS AND METHODS FOR INHIBITION OF ANGIOGENESIS AND LYMPHANGIOGENESIS<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'ANGIOGENÈSE ET LA LYMPHANGIOGENÈSE
    申请人:TEXAS A & M UNIV SYS
    公开号:WO2015123392A1
    公开(公告)日:2015-08-20
    A composition including a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof is disclosed. The composition includes an amount and formulation of the rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof sufficient to inhibit one or more of angiogenesis and lymphangiogenesis in an organism and/or sufficient to induce drug-sensitization in or inhibition of a cancer cell in the organism.
    本发明揭示了一种包括利福霉素生物或其药学上可接受的盐、合物或前药的组合物。该组合物包括足以抑制生物体内一种或多种血管生成和淋巴管生成的利福霉素生物或其药学上可接受的盐、合物或前药的数量和配方,以及足以诱导生物体内癌细胞的药物敏感性或抑制癌细胞的数量和配方。
  • Compositions and methods for drug sensitization of parasites
    申请人:Sacchettini James C.
    公开号:US10226455B2
    公开(公告)日:2019-03-12
    Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
    本研究提供了抑制寄生虫和/或使寄生虫对抗寄生虫药物敏感或再敏感的组合物和方法。这些组合物可以包含利福霉素生物或其药学上可接受的盐、合物或原药,其用量和制剂足以抑制寄生虫或诱导寄生虫对药物敏感。所述方法可包括向寄生虫施用利福霉素生物或其药学上可接受的盐、合物或原药,其用量和制剂足以抑制或诱导寄生虫药敏化。
  • COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL
    申请人:Sacchettini James
    公开号:US20140314878A1
    公开(公告)日:2014-10-23
    The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
  • COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES
    申请人:The Texas A&M University System
    公开号:US20190142817A1
    公开(公告)日:2019-05-16
    Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
  • US9134329B2
    申请人:——
    公开号:US9134329B2
    公开(公告)日:2015-09-15
查看更多